Anat Hakim Sells 5,000 Shares of Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $44.29 during mid-day trading on Monday, hitting $1,230.00. The company’s stock had a trading volume of 2,928,651 shares, compared to its average volume of 3,143,000. Eli Lilly and Company has a one year low of $625.90 and a one year high of $1,249.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The firm has a market capitalization of $1.16 trillion, a PE ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The stock’s 50-day moving average is $1,159.38 and its two-hundred day moving average is $1,047.62.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 36.77 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 23.22%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Berenberg Bank boosted their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research note on Monday, June 22nd. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a report on Friday, May 22nd. Guggenheim boosted their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Bank of America raised their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Finally, Citigroup boosted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,292.18.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Lilly reported $22.97 billion in second-quarter revenue, up 47.7% year over year, while adjusted earnings of $8.38 per share exceeded consensus by $1.98. The company raised its 2026 outlook, including a midpoint revenue target of approximately $86 billion and adjusted EPS guidance of $35.50 to $36.50. LLY Q2 Deep Dive: Key Products and Pipeline Expansion
• Positive Sentiment: The obesity-drug opportunity remains the main growth catalyst. Analysts argue that Lilly’s next leg of growth could come from an oral obesity treatment, potentially expanding access through additional prescribers and payers beyond injectable therapies. Lilly’s expected regulatory filing timeline also increases competitive pressure on Novo Nordisk in the GLP-1 market. Eli Lilly Stock’s Next Climb Runs Through a Pill, Not Just an Injection
• Positive Sentiment: Lilly is broadening its pipeline beyond diabetes and obesity. Its olomorasib cancer drug received FDA Breakthrough Therapy designation for certain patients with advanced pancreatic cancer, and Lilly entered a trial collaboration to evaluate the drug in lung cancer. The company also participated in Remedium Bio’s $10 million Series A financing, supporting potential future biotechnology partnerships. Eli Lilly Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
• Neutral Sentiment: Investor expectations are elevated. Lilly’s strong growth and leadership in GLP-1 drugs have made it a preferred “top dog” for investors, but its premium valuation leaves the stock sensitive to execution, regulatory, reimbursement, and competitive developments. Nvidia, Eli Lilly, and Disney Show It’s Time to Back the Top Dogs

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. BlackRock Inc. grew its stake in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after buying an additional 1,046,558 shares during the last quarter. State Street Corp grew its stake in Eli Lilly and Company by 1.8% during the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after buying an additional 635,358 shares during the last quarter. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares in the last quarter. Finally, Capital World Investors raised its stake in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after acquiring an additional 61,851 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.